Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado M C, Martín Sánchez F J, Martínez-Sellés M, Molero García J M, Moreno Guillén S, Rodríguez-Artalejo F J, Bouza E
Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain.
Rev Esp Quimioter. 2021 Oct;34(5):408-418. doi: 10.37201/req/035.2021. Epub 2021 Apr 28.
After the start of vaccination against SARS-CoV-2, enough clinical experience is already accumulating, in the real world and outside clinical trials, to resolve some of the questions that are still pending about this problem. The Scientific Committee on COVID-19 of the Madrid College of Physicians has discussed and reviewed some of these issues with a multidisciplinary approach. The following document is an attempt to answer some of these questions with the information available so far. This document is structured in questions on different aspects of the indications, efficacy and tolerance of anti-COVID-19 vaccination.
在开始接种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗后，在现实世界和临床试验之外已经积累了足够的临床经验，以解决有关该问题仍悬而未决的一些问题。马德里医师学院的COVID-19科学委员会已采用多学科方法讨论并审查了其中一些问题。以下文件试图利用目前可用的信息回答其中一些问题。本文档围绕抗COVID-19疫苗接种的适应症、疗效和耐受性等不同方面的问题展开。
